Speaker: Dr Mary Keir PhD, Genetech Inc, South San Francisco
Venue: L2.6, 2ND Floor, William Leech Building, Medical School
Date and time: Monday 1st December 2014 at 1.00pm
Dr Mary Keir will present
“Predictive biomarkers for response to etrolizumab therapy in IBD”
Biog: Mary Keir received her Ph.D. in Biomedical Sciences at the University of California, San Francisco, where her thesis work focused on innate responses to HIV infection in the human thymus. Following completion of her Ph.D, she undertook postdoctoral training at Harvard Medical School, where she studied the role of PD-1:PD-L1 interactions in T cell tolerance and autoimmunity. Mary next moved to Genentech to join the Immunology Diagnostic Discovery group and focus on biomarker identification and utility in clinical trials. At Genentech, she has led biomarker efforts in both systemic lupus erythematosus and inflammatory bowel disease (IBD). Her current research focus is on predictive biomarkers of inflammatory subgroups in IBD as well as prognostic biomarkers of disease.
Jenna Ho
PA to:
Professor John Isaacs, Director of the Institute of Cellular Medicine
Professor Neil Sheerin, Professor of Nephrology
4th Floor William Leech Building
Medical School
Newcastle University
Framlington Place
Newcastle Upon Tyne
NE2 4HH
Tel: 0191 208 6227
Fax: 0191 208 5066
Email: jenna.ho@newcastle.ac.uk
No comments:
Post a Comment
Note: only a member of this blog may post a comment.